Zyrova C 10 Capsule is a combination pharmaceutical formulation containing Rosuvastatin 10 mg and Clopidogrel 75 mg, designed to manage cardiovascular conditions by addressing lipid abnormalities and preventing thrombotic events. Rosuvastatin, a potent HMG-CoA reductase inhibitor, effectively lowers low-density lipoprotein cholesterol (LDL-C) and triglycerides while modestly increasing high-density lipoprotein cholesterol (HDL-C), thereby reducing the risk of atherosclerosis and associated cardiovascular complications. Clopidogrel, an antiplatelet agent, inhibits the ADP-mediated activation of platelet aggregation, thereby reducing the risk of stroke, myocardial infarction, and other thrombotic events in patients with a history of acute coronary syndrome or peripheral arterial disease. The combination therapy is particularly beneficial in patients requiring simultaneous lipid control and platelet inhibition to prevent recurrent cardiovascular events. Zyrova C 10 Capsule should be administered under medical supervision with appropriate monitoring of lipid profiles, liver function, and bleeding parameters. Caution is advised in patients with hepatic impairment, bleeding disorders, or those receiving concomitant anticoagulant therapy. Adherence to prescribed dosage and lifestyle modifications enhances therapeutic outcomes and minimizes adverse effects. This combination capsule offers a convenient and effective approach to comprehensive cardiovascular risk management.